|
|
 |
|
Viewing report
|
|
|
Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011
Medpredict, Sep 2011, Pages: 158
Multiple Sclerosis Thought Leader Panel #14 highlights a series of interviews conducted with experts in September, 2011. For this Panel Medpredict asked their Thought Leaders to engage in a thought exercise with them. The purpose was to designate their “fantasy formulary”, comprised of the top seven therapeutics, currently in the development pipeline, that they want to see available for use in the prevention/treatment of multiple sclerosis. They allowed Panelists to choose the class of drug, a specific drug (if they had a preference), the unmet needs to be addressed and the benefits that they expected their choices to deliver. The panel’s responses are just as enlightening regarding what they would NOT put on their fantasy formularies.
|
|
|
|
